Table 1. Characteritics and outcome for patients subjected to molecular analyses compared with those for the intention-to-treat (ITT) population of the LETS study.
| Somatic mutation analysis (n = 275) |
Fusion gene analysis (n = 240) |
MET amplification analysis (n = 229) |
ITT population (n = 564) |
|
|---|---|---|---|---|
| Characteristic | ||||
| CBDCA+PTX/CBDCA+S-1 | 136 (49%)/139 (51%) | 117 (49%)/123 (51%) | 113 (49%)/116 (51%) | 282 (50%)/282 (50%) |
| Median age (range), years | 63 (36–74) | 64 (36–74) | 63 (36–74) | 64 (36–74) |
| Male/female | 211 (77%)/64 (23%) | 184 (77%)/56 (23%) | 178 (78%)/51 (22%) | 433 (77%)/131 (23%) |
| ECOG PS 0/1 | 76 (28%)/199 (72%) | 63 (26%)/177 (74%) | 62 (27%)/167 (73%) | 177 (31%)/387 (69%) |
| Clinical stage IIIB/IV | 68 (25%)/207 (75%) | 59 (25%)/181 (75%) | 60 (26%)/169 (74%) | 136 (24%)/428 (76%) |
| Nonsmoker/smoker | 49 (18%)/226 (82%) | 44 (18%)/196 (82%) | 38 (17%)/191 (83%) | 104 (18%)/460 (82%) |
| Outcome | ||||
| PFS hazard ratio (95% CI) | 0.88 (0.70–1.12) | 0.95 (0.74–1.24) | 0.83 (0.64–1.09) | 1.04 (0.86–1.22) |
| OS hazard ratio (95% CI) | 0.93 (0.71–1.21) | 0.85 (0.64–1.13) | 0.91 (0.68–1.21) | 0.96 (0.79–1.15) |
Abbreviations: CBDCA, carboplatin; PTX, paclitaxel; ECOG, Eastern Cooperative Oncology Group; PS, performance status; PFS, progression-free survival; CI, confidence interval; OS, overall survival.